The key hypothesis of this proposal holds that the connective tissue activation process, mediated by potent cytokines drives many of the events of inflammation, influencing both reparative (proliferative) and destructive mechanisms. We propose to define the manner in which the cytokine, CTAP-III, initiates and sustains connective tissue activation, and to define its pathogenetic roles in inflammation. Construction of recombinant CTAP-III molecules and synthetic peptides of both native and novel configuration offers opportunities to develop new tactics to influence key sites in the inflammatory process. Our ultimate goal is to devise agents or procedures which favorably modify inflammation in man, including suppressing the process (as in rheumatoid arthritis), and enhancing aspects of normal physiology (as in wound healing). Knowledge of the structure of connective tissue activating peptide-III (CTAP-III) is critical to understanding structure-function relationships through which this cytokine expresses its biological effects. To delineate CTAP-III structure-function relationships, we will determine the residues or sequences critical to the anabolic, chemotactic and other activities in normal, OA and rheumatoid synovial cell cultures. This will be accomplished: (1) by chemical modifications of CTAP-III, (2) by construction of relevant synthetic peptides, and (3) by site directed mutagenesis of recombinant CTAP-III. The direct structure-function studies will be extended by collaborative efforts to define the three dimensional structure of CTAP-III by X-ray crystallographic and Nuclear Magnetic Resonance studies. The mechanisms/s by which CTAP-III activates connective tissue cells will be clarified by receptor binding studies and definition of possible co- ligands critical to CTAP-III dependent connective cell activation. The roles of (1) CTAP-III binding to proteoglycans of cell membranes and extracellular matrix and putative heparanase activity, and (2) CTAP-III induction of cytokines in sustaining the activated state of normal, OA, and RA synovial cells will be studied to clarify the biologic basis of chronic inflammation.

Agency
National Institute of Health (NIH)
Institute
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
Type
Research Project (R01)
Project #
5R01AR010728-30
Application #
2732809
Study Section
General Medicine A Subcommittee 2 (GMA)
Project Start
1978-02-01
Project End
2000-06-30
Budget Start
1998-07-01
Budget End
2000-06-30
Support Year
30
Fiscal Year
1998
Total Cost
Indirect Cost
Name
University of Michigan Ann Arbor
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
791277940
City
Ann Arbor
State
MI
Country
United States
Zip Code
48109
Castor, C William; Kotlyar, Alina; Edwards, Brian E (2002) Connective tissue activation XXXVIII: heparin/heparanase activity of human platelets resides in a high molecular weight protein, not in connective tissue activating peptide III. J Rheumatol 29:2337-44
Castor, C W; Smith, E M; Bignall, M C et al. (1997) Connective tissue activation. XXXVII. Effects of cytokine combinations, implications for an integrated cytokine network. J Rheumatol 24:2080-9
Cabral, A R; Castor, C W (1996) Connective tissue activating peptide-V and CD59: a molecule in search of a job. J Rheumatol 23:1126-9
Castor, C W; Andrews, P C; Swartz, R D et al. (1993) Connective tissue activation. XXXVI. The origin, variety, distribution, and biologic fate of connective tissue activating peptide-III isoforms: characteristics in patients with rheumatic, renal, and arterial disease. Arthritis Rheum 36:1142-53
Castor, C W; Smith, E M; Hossler, P A et al. (1992) Connective tissue activation. XXXV. Detection of connective tissue activating peptide-III isoforms in synovium from osteoarthritis and rheumatoid arthritis patients: patterns of interaction with other synovial cytokines in cell culture. Arthritis Rheum 35:783-93
Tai, P K; Liao, J F; Hossler, P A et al. (1992) Regulation of glucose transporters by connective tissue activating peptide-III isoforms. J Biol Chem 267:19579-86
Castor, C W; Smith, E M; Bignall, M C et al. (1991) Preparation and bioassay of connective tissue activating peptide III and its isoforms. Methods Enzymol 198:405-16
Castor, C W; Walz, D A; Johnson, P H et al. (1990) Connective tissue activation. XXXIV: Effects of proteolytic processing on the biologic activities of CTAP-III. J Lab Clin Med 116:516-26
Sisson, T H; Castor, C W (1990) An improved method for immobilizing IgG antibodies on protein A-agarose. J Immunol Methods 127:215-20
Castor, C W; Walz, D A; Ragsdale, C G et al. (1989) Connective tissue activation. XXXIII. Biologically active cleavage products of CTAP-III from human platelets. Biochem Biophys Res Commun 163:1071-8

Showing the most recent 10 out of 11 publications